Document is current
Any future updates will be listed below
-
Authors
Kevlicius, Lukas https://orcid.org/0000-0003-3536-3701
Cepulyte, Ruta
Vasilevska, Dominika
Griskevicius, Laimonas
Zucenka, Andrius https://orcid.org/0000-0002-5520-1534
- License Information
-
More Information
Article History
Received: 7 February 2022
Revised: 3 April 2022
Accepted: 5 April 2022
First Online: 16 April 2022
Competing interests
: LK: None. RC: None. DV: None. LG: <i>AbbVie</i>—travel expenses. AZ: <i>Jannsen</i>—honoraria, travel expenses; <i>Takeda</i>—travel expenses; <i>Novartis</i>—honoraria, travel expenses; <i>Pfizer</i>—honoraria, travel expenses; <i>Astellas</i>—honoraria; <i>AbbVie</i>—honoraria, travel expenses.
: The data collection was approved by Vilnius Regional Biomedical Research Ethics Committee (rbtek@mf.vu.lt, approval No. 2019/2-1088-591) and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients for being included in the study.
